The world cancer immunotherapy market is expected to grow at a CAGR of 11.4% in the second half of the forecast period. The market reached $63bn in 2018, dominated by the monoclonal antibody segment which held 66% share of the market.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 194-page report you will receive 110 tables and 93 figures– all unavailable elsewhere.
The 194-page report provides clear detailed insight into the global cancer-treating drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global cancer immunotherapy market forecasts from 2019-2029
• This report also breaks down the revenue forecast for the global cancer immunotherapy market by Technology: • Monoclonal Antibodies • Cytokines & immunomodulators • Others (Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy)
Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.
• This report also breaks down the revenue forecast for the global cancer immunotherapy market by Application: • Lung Cancer • Breast Cancer • Colorectal cancer • Melanoma Cancer • Prostate Cancer • Head & Neck Cancer, • Others (Renal Cell Carcinoma, Cervical, Gastric, Lymphoma)
Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.
• This report also breaks down the revenue forecast for the world cancer immunotherapy market by End-User: • Hospitals • Cancer Research Centers • Clinics
Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.
• This report provides individual revenue forecasts to 2029 for these regional and national markets: • North America: US, Canada, Mexico • South America: Brazil, Argentina, Paraguay, Bolivia, Rest of South America • Europe: The UK, Germany, France, Spain, Italy, Rest of Europe • Asia-Pacific: China, Japan, India, Australia, Thailand, Rest of Asia-Pacific • Rest of World: Middle East, Africa, Other Countries
Each regional market is further broken down by technology, application and end-user.
• This report discusses trends in the industry and assesses drivers and restraints, as well as opportunities and threats. It also includes porters’ five force analysis; threat of new entrants, power of suppliers, power of buyers, rivalry among competitors and threat of substituents.
• Our study discusses the selected leading companies that are the major players in the cancer immunotherapy market: • Adaxic Inc • AstraZeneca • Bayer • Bristol-Myers Squibb (BMS) • Eli Lilly and Co. • Medtronic Plc • Merck & Co., Inc. (Merck) • Novartis • Pfizer • Roche
The report provides overviews of the companies, financial information, product portfolio, pipeline products and recent developments.
Visiongain’s study is intended for anyone requiring commercial analyses for the global cancer Immunotherapy market. You find data, trends and predictions.
Buy our report today Global Cancer Immunotherapy Market Forecast 2019-2029: Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Hospitals, Cancer Research Centers, Clinics.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Global Cancer Immunotherapy Market Overview 1.2 Market Definition 1.3 Research Methodology 1.3.1 Primary Research 1.3.2 Secondary Research 1.3.3 Market Evaluation & Forecasting Methodology 1.4 Global Cancer Immunotherapy Market Segmentation 1.5 Overview of Findings 1.6 Why You Should Read This Report 1.7 How this report delivers? 1.8 Key Questions Answered by This Analytical Report 1.9 Frequently Asked Questions (FAQ) 1.10 Who is This Report For? 1.11 Associated Visiongain Reports 1.12 About Visiongain
2. Introduction to Cancer Immunotherapy Market
3. Global Cancer Immunotherapy Market Forecast 2019 - 2029 4. Global Cancer Immunotherapy Market by Technology: Market Forecast 2019 - 2029 4.1 Overview 4.2 Monoclonal antibodies 4.3 Cytokines & Immunomodulators 4.4 Others (Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy)
5. Global Cancer Immunotherapy Market by Application: Market Forecast 2019 - 2029 5.1 Overview 5.2 Lung Cancer 5.3 Breast Cancer 5.4 Colorectal Cancer 5.5 Melanoma 5.6 Prostate Cancer 5.7 Head & Neck Cancer 5.8 Other Cancer types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma)
6. Global Cancer Immunotherapy Market by End-User: Market Forecast 2019 - 2029 6.1 Hospitals 6.2 Cancer Research Centres 6.3 Clinics
7. Regional Cancer Immunotherapy Market Forecasts 2019-2029 7.1 Regional Cancer Immunotherapy Market Forecast 2018-2029 7.2 North American Cancer Immunotherapy Market Forecast 2018-2029 7.2.1 USA Cancer Immunotherapy Market Forecast 2018-2029 7.2.2 Canada Cancer Immunotherapy Market Forecast 2018-2029 7.2.3 Mexico Cancer Immunotherapy Market Forecast 2018-2029 7.3 South American Cancer Immunotherapy Market Forecast 2018-2029 7.3.1 Brazil Cancer Immunotherapy Market Forecast 2018-2029 7.3. 2 Argentina Cancer Immunotherapy Market Forecast 2018-2029 7.3.3 Paraguay Cancer Immunotherapy Market Forecast 2018-2029 7.3.4 Bolivia Cancer Immunotherapy Market Forecast 2018-2029 7.3.5 Rest of South America Cancer Immunotherapy Market Forecast 2018-2029 7.4 European Cancer Immunotherapy Market Forecast 2018-2029 7.4.1 France Cancer Immunotherapy Market Forecast 2018-2029 7.4.2 Germany Cancer Immunotherapy Market Forecast 2018-2029 7.4.3 UK Cancer Immunotherapy Market Forecast 2018-2029 7.4.4 Spain Cancer Immunotherapy Market Forecast 2018-2029 7.4.5 Italy Cancer Immunotherapy Market Forecast 2018-2029 7.4.6 Rest of Europe Cancer Immunotherapy Market Forecast 2018-2029 7.5 Asia-Pacific Cancer Immunotherapy Market Forecast 2018-2029 7.5.1 China Cancer Immunotherapy Market Forecast 2018-2029 7.5.2 Japan Cancer Immunotherapy Market Forecast 2018-2029 7.5.3 India Cancer Immunotherapy Market Forecast 2018-2029 7.5.4 Australia Cancer Immunotherapy Market Forecast 2018-2029 7.5.5 Thailand Cancer Immunotherapy Market Forecast 2018-2029 7.5.6 Rest of Asia-Pacific Cancer Immunotherapy Market Forecast 2018-2029 7.6 Rest of World Cancer Immunotherapy Market Forecast 2018-2029 7.6.1 Middle East Cancer Immunotherapy Market Forecast 2018-2029 7.6.2 Africa Cancer Immunotherapy Market Forecast 2018-2029 7.6.3 Other Countries Cancer Immunotherapy Market Forecast 2018-2029
8. Cancer Immunotherapy Market: Qualitative Analysis 8.1 Porter’s Five Forces Analysis of the Cancer Immunotherapy Market 8.2 Bargaining Power of Buyers (Low) 8.3 Bargaining Power of Suppliers (High) 8.4 Threat of New Entrants (Low) 8.5 Threat of Substitute Products (High) 8.6 Intensity of Competitive Rivalry (High) 8.7 Drivers & Restrains 8.8 Increasing Prevalence of Cancer 8.9 Increasing Research in Cancer Immunotherapy 8.10 High Cost of Cancer Immunotherapy 8.11 Increasing Funding for the Cancer Research by Governmental Organisations 8.12 Increasing Investment from Government, Public and Private Sector 8.13 Increased Focus Towards Advanced Treatment Protocols 8.14 Significant Unmet Need in Cancer Diagnosis 8.15 Increased Awareness to Reduce Healthcare Costs 8.16 Opportunities in Emerging Economies
9. Leading Companies in Cancer Immunotherapy Market 9.1 F. Hoffmann-La Roche AG 9.1.1 F. Hoffmann-La Roche AG: Company Overview 9.1.2 F. Hoffmann-La Roche AG: Business Performance 9.1.3 F. Hoffmann-La Roche AG: Product Portfolio 9.1.4 F. Hoffmann-La Roche AG: Recent Developments 9.2 Merck & Co., Inc. 9.2.1 Merck & Co., Inc.: Company Overview 9.2.2 Merck & Co., Inc.: Business Performance 9.2.3 Merck & Co., Inc.: Product Portfolio 9.2.4 Merck & Co., Inc.: Recent Development 9.3 Medtronic plc. 9.3.1 Medtronic plc.: Company Overview 9.3.2 Medtronic plc.: Business Performance 9.3.3 Medtronic plc.: Product Portfolio 9.3.4 Medtronic plc.: Recent Developments 9.4 Bristol-Myers Squibb 9.4.1 Bristol-Myers Squibb: Company Overview 9.4.2 Bristol-Myers Squibb: Business Performance 9.4.3 Bristol-Myers Squibb: Product Portfolio 9.4.4 Bristol-Myers Squibb: Recent Developments 9.5 Novartis AG 9.5.1 Novartis AG: Company Overview 9.5.2 Novartis AG: Business Performance 9.5.3 Novartis AG: Product Portfolio 9.5.4 Novartis AG: Recent Developments 9.6 Pfizer Inc. 9.6.1 Pfizer Inc.: Company Overview 9.6.2 Pfizer Inc.: Business Performance 9.6.3 Pfizer Inc.: Product Portfolio 9.6.4 Pfizer Inc.: Recent Developments 9.7 Bayer AG 9.7.1 Bayer AG: Company Overview 9.7.2 Bayer AG: Business Performance 9.7.3 Bayer AG: Product Portfolio 9.7.4 Bayer AG: Recent Development 9.8 AstraZeneca Plc. 9.8.1 AstraZeneca Plc.: Company Overview 9.8.2 AstraZeneca Plc.: Business Performance 9.8.3 AstraZeneca Plc.: Product Portfolio 9.9 Eli Lilly and Company 9.9.1 Eli Lilly and Company: Company Overview 9.9.2 Eli Lilly and Company: Business Performance 9.9.3 Eli Lilly and Company: Product Portfolio 9.9.4 Eli Lilly and Company: Recent Development 9.10 Advaxis, Inc. 9.10.1 Advaxis, Inc.: Recent Development 9.10.2 Advaxis, Inc.: Business Performance 9.10.3 Advaxis, Inc.: Recent Development 10. Conclusions 10.1 Current Leading Segments 10.2 Leading Regional Markets 10.3 Emerging Markets 10.4 The Future of the Market?
Associated Visiongain Reports Visiongain Report Sales Order Form Appendix A About Visiongain Appendix B Visiongain report evaluation form
List of Tables Table 2.1. Worldwide Estimated Incidence and Prevalence of all Cancer Types, (2012) Table 3.1. Global Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%) 2018-2029 Table 4.1. Global Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029 Table 4.2. Types of Monoclonal Antibodies Table 4.3. Therapeutic Monoclonal Antibodies Approved by FDA Table 4.4. Global Monoclonal Antibodies for Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 4.5. Global Monoclonal Antibodies for Cancer Immunotherapy Market Forecast by Geography: ($m, AGR%, CAGR%) 2018-2029 Table 4.6. Global Cytokines & Immunomodulators for Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 4.7. Global Cytokines & Immunomodulators for Cancer Immunotherapy Market Forecast by Geography:($m, AGR%, CAGR%), 2018-2029 Table 4.8. Global Others Technologies for Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 4.9. Global Other Technologies for Cancer Immunotherapy Market Forecast by Geography: ($m, AGR%, CAGR%), 2018-2029 Table 5.1. Top Cancer Type in 2012 Table 5.2. Global Cancer Immunotherapy Market by Application: ($m, AGR%, CAGR%), 2018-2029 Table 5.3. Types of Monoclonal Antibodies Table 5.4. Global Cancer Immunotherapy Market for Lung Cancer: ($m, AGR%, CAGR%), 2018-2029 Table 5.5. Global Cancer Immunotherapy Market for Lung Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029 Table 5.6. Global Cancer Immunotherapy Market for Breast Cancer: ($m, AGR%, CAGR%), 2018-2029 Table 5.7. Global Cancer Immunotherapy Market for Breast Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029 Table 5.8. Global Cancer Immunotherapy Market for Colorectal Cancer: ($m, AGR%, CAGR%), 2018-2029 Table 5.9. Global Cancer Immunotherapy Market for Colorectal Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029 Table 5.10. Global Cancer Immunotherapy Market for Melanoma Cancer: ($m, AGR%, CAGR%), 2018-2029 Table 5.11. Global Cancer Immunotherapy Market for Melanoma Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029 Table 5.12. Global Cancer Immunotherapy Market for Prostate Cancer: ($m, AGR%, CAGR%), 2018-2029 Table 5.13. Global Cancer Immunotherapy Market for Prostate Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029 Table 5.14. Global Cancer Immunotherapy Market for Head & Neck Cancer: ($m, AGR%, CAGR%), 2018-2029 Table 5.15. Global Cancer Immunotherapy Market for Head & Neck Cancer by Geography: ($m, AGR%, CAGR%), 2018-2029 Table 5.16. Global Cancer Immunotherapy Market for Other Cancer types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma): ($m, AGR%, CAGR%) 2018-2029 Table 5.17. Global Cancer Immunotherapy Market for Other Cancer Types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma) by Geography: ($m, AGR%, CAGR%), 2018-2029 Table 6.1. Global Cancer Immunotherapy Market by End-User: ($m, AGR%, CAGR%), 2018-2029 Table 6.2. Global Cancer Immunotherapy Market Forecast for Hospital: ($m, AGR%, CAGR%), 2018-2029 Table 6.3. Global Cancer Immunotherapy Market Forecast for Hospital by Geography: ($m, AGR%, CAGR%), 2018-2029 Table 6.4. Funding Received by NCI ($m) Table 6.5. Current Grants by Cancer Type as of August 2018 Table 6.6. Global Cancer Immunotherapy Market for Cancer Research Centres: ($m, AGR%, CAGR%), 2018-2029 Table 6.7. Global Cancer Immunotherapy Market Forecast for Cancer Research Centres by Geography: ($m, AGR%, CAGR%), 2018-2029 Table 6.8. Global Cancer Immunotherapy Market Forecast for Clinic: ($m, AGR%, CAGR%), 2018-2029 Table 6.9. Global Cancer Immunotherapy Market Forecast for Clinic by Geography: ($m, AGR%, CAGR%), 2018-2029 Table 7.1. Global Cancer Immunotherapy Market Forecast by Geography: ($m, AGR%, CAGR%), 2018-2029 Table 7.2. North America Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029 Table 7.3. North America Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029 Table 7.4. North America Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029 Table 7.5. North America Cancer Immunotherapy Market Forecast by End User: ($m, AGR%, CAGR%), 2018-2029 Table 7.6. US Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.7. Canada Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.8. Mexico Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.9. South America Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029 Table 7.10. South America Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029 Table 7.11. South America Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029 Table 7.12. South America Cancer Immunotherapy Market Forecast by End User: ($m, AGR%, CAGR%), 2018-2029 Table 7.13. Brazil Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.14. Argentina Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.15. Paraguay Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.16. Bolivia Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.17. Rest of South America Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.18. European Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029 Table 7.19. European Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029 Table 7.20 European Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029 Table 7.21 European Cancer Immunotherapy Market Forecast by End-User: ($m, AGR%, CAGR%), 2018-2029 Table 7.22. France Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.23. Germany Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.24. UK Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.25. Spain Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.26. Italy Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.27. Rest of European Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.28. Asia-Pacific Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029 Table 7.29. Asia-Pacific Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%,), 2018-2029 Table 7.30. Asia-Pacific Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029 Table 7.31 Asia-Pacific Cancer Immunotherapy Market Forecast by End- User: ($m, AGR%, CAGR%), 2018-2029 Table 7.32. China Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.33. Japan Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.34. India Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.35. Australia Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.36. Thailand Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.37. Rest of Asia-Pacific Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.38. Rest of World Cancer Immunotherapy Market Forecast by Country: ($m, AGR%, CAGR%), 2018-2029 Table 7.39. Rest of World Cancer Immunotherapy Market Forecast by Technology: ($m, AGR%, CAGR%), 2018-2029 Table 7.40 Rest of World Cancer Immunotherapy Market Forecast by Application: ($m, AGR%, CAGR%), 2018-2029 Table 7.41 Rest of World Cancer Immunotherapy Market Forecast by End-User: ($m, AGR%, CAGR%), 2018-2029 Table 7.42. Middle East Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.43. Africa Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 7.44. Other Countries Cancer Immunotherapy Market Forecast: ($m, AGR%, CAGR%), 2018-2029 Table 9.1. F. Hoffmann-La Roche AG: Company Overview Table 9.2. F. Hoffmann-La Roche AG: Product Portfolio Table 9.3. F. Hoffmann-La Roche AG: Recent Developments Table 9.4. Merck & Co., Inc.: Company Overview Table 9.5. Merck & Co., Inc.: Product Portfolio Table 9.6. Merck & Co., Inc.: Recent Development Table 9.7. Medtronic plc.: Company Overview Table 9.8. Medtronic plc.: Product Portfolio Table 9.9. Medtronic plc.: Recent Developments Table 9.10. Bristol-Myers Squibb: Company Overview Table 9.11. Bristol-Myers Squibb: Product Portfolio Table 9.12. Bristol-Myers Squibb: Recent Developments Table 9.13 Novartis AG: Company Overview Table 9.14. Novartis AG: Product Portfolio Table 9.15. Novartis AG: Recent Developments Table 9.16. Pfizer Inc.: Company Overview Table 9.17. Pfizer Inc.: Product Portfolio Table 9.18. Pfizer Inc.: Recent Development Table 9.19. Bayer AG: Company Overview Table 9.20. Bayer AG: Product Portfolio Table 9.21. Bayer AG: Recent Development Table 9.22. AstraZeneca Plc.: Company Overview Table 9.23. AstraZeneca Plc.: Product Portfolio Table 9.24. Eli Lilly and Company: Company Overview Table 9.25. Eli Lilly and Company: Product Portfolio Table 9.26. Eli Lilly and Company: Recent Development Table 9.27. Advaxis, Inc.: Company Overview Table 9.28. Advaxis, Inc.: Recent Developments Table 10.1 Worldwide Estimated Prevalence of Cancer, 2012 List of Figures Figure 1.1. Cancer immunotherapy Market Segmentation Figure 2.1 Top winning Strategies of Market Players in Cancer Immunotherapy, 2014-2018 Figure 3.1 Cancer Immunotherapy Market by Technology: ($m), 2018-2029 Figure 3.2 Cancer Immunotherapy Market by Application: ($m), 2018-2029 Figure 3.3 Cancer Immunotherapy Market by End-User: ($m), 2018-2029 Figure 4.1 Cancer Immunotherapy Market by Technology: Market Share (%), 2018 Figure 4.2 Cancer Immunotherapy Market by Technology: Forecast ($m) 2018-2029 Figure 4.3 Global Monoclonal Antibodies for Cancer Immunotherapy Market Forecast by Geography: ($m) 2018-2029 Figure 4.4 Global Cytokines & Immunomodulators for Cancer Immunotherapy Market Forecast by Geography: ($m), 2018-2029 Figure 4.5 Global Other Technologies for Cancer Immunotherapy Market Forecast by Geography: ($m), 2018-2029 Figure 5.1. Global Cancer Immunotherapy Market by Application: ($m), 2018-2029 Figure 5.2. Global Cancer Immunotherapy Market by Application: Market Share (%), 2018 Figure 5.3. Global Cancer Immunotherapy Market for Lung Cancer Forecast by Geography: ($m), 2018-2029 Figure 5.4. Global Cancer Immunotherapy Market for Breast Cancer Forecast by Geography: ($m), 2018-2029 Figure 5.5. Global Cancer Immunotherapy Market for Colorectal Cancer Forecast, by Geography: ($m), 2018-2029 Figure 5.6. Global Cancer Immunotherapy Market for Melanoma Cancer Forecast by Geography: ($m), 2018-2029 Figure 5.7. Global Cancer Immunotherapy Market for Prostate Cancer Forecast, by Geography: ($m), 2018-2029 Figure 5.8. Global Cancer Immunotherapy Market for Head & Neck Cancer Forecast by Geography: ($m), 2018-2029 Figure 5.9. Global Cancer Immunotherapy Market for Other Cancer types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma) Forecast by Geography: ($m), 2018-2029 Figure 6.0. Global Cancer Immunotherapy Market Forecast by End-User: ($m), 2018-2029 Figure 6.1 Global Cancer Immunotherapy Market by End-User: Market Share (%), 2018 Figure 6.2. Global Cancer Immunotherapy Market Forecast for Hospital by Geography: ($m), 2018-2029 Figure 6.3. Global Cancer Immunotherapy Market Forecast for Cancer Research Centres by Geography: ($m), 2018-2029 Figure 6.4 Global Cancer Immunotherapy Market Forecast for Clinic by Geography: ($m), 2018-2029 Figure 7.1. Global Cancer Immunotherapy Market Forecast by Geography: ($m), 2018-2029 Figure 7.2. Global Cancer Immunotherapy Market Forecast by Geography: Market Share (%), 2018 Figure 7.3. North America Cancer Immunotherapy Market by Country: Market Share (%), 2018 Figure 7.4. US Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.5. Estimation of diagnosis of Canadian Cancer Immunotherapy Figure 7.6. Cancer Immunotherapy Market Forecast ($m), 2018-2029 Figure 7.7 Mexico Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.8 South America Cancer Immunotherapy Market Forecast by Country: ($m), 2018-2029 Figure 7.9 South America Cancer Immunotherapy Market by Country: Market Share (%), 2018 Figure 7.10. Brazil Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.11. Argentina Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.12. Paraguay Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.13. Bolivia Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.14. Rest of South America Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.15. Europe Cancer Immunotherapy Market Forecast by Country: ($m), 2018-2029 Figure 7.16. Europe Cancer Immunotherapy Market by Country: Market Share (%), 2018 Figure 7.17. France Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.18. Germany Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.19. UK Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.20. Spain Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.21. Italy Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.22. Rest of Europe Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.23. Asia-Pacific Cancer Immunotherapy Market Forecast by Country ($m) 2018-2029 Figure 7.24. Asia-Pacific Cancer Immunotherapy Market: Market Share (%), 2018 Figure 7.25. China Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.26. Japan Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.27. India Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.28. Australia Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.29. Thailand Cancer Immunotherapy Market Forecast: ($m,) 2018-2029 Figure 7.30. Rest of Asia-Pacific Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.31. RoW Cancer Immunotherapy Market Forecast by Country: ($m), 2018-2029 Figure 7.32. Rest of World Cancer Immunotherapy Market by Country: Market Share (%), 2018 Figure 7.33. Middle East Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.34. Africa Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 7.35. Other Countries Cancer Immunotherapy Market Forecast: ($m), 2018-2029 Figure 8.1 Porter’s Five Forces Analysis of the Cancer Immunotherapy Market Figure 9.1. F. Hoffmann-La Roche AG: Historical Revenue: ($m), 2013-2017 Figure 9.2. F. Hoffmann-La Roche AG: Product Segments Share (%), 2017 Figure 9.3. F. Hoffmann-La Roche AG: Geographical Presence Share (%), 2017 Figure 9.4. Merck & Co., Inc.: Historical Revenue ($m), 2013–2017 Figure 9.5. Merck & Co., Inc.: Product Segments Share (%), 2017 Figure 9.6. Merck & Co., Inc.: Geographical Presence Share (%), 2017 Figure 9.7. Medtronic plc.: Historical Revenue ($m), 2014-2018 Figure 9.8. Medtronic plc.: Product Segments Share (%), 2018 Figure 9.9. Medtronic plc.: Geographical Presence Share (%), 2018 Figure 9.10. Bristol-Myers Squibb: Historical Revenue ($m), 2013-2017 Figure 9.11. Bristol-Myers Squibb: Product Segments Share (%), 2017 Figure 9.12. Bristol-Myers Squibb: Geographical Presence Share (%), 2017 Figure 9.13. Novartis AG: Historical Revenue ($m), 2013-2017 Figure 9.14. Novartis AG: Product Segments Share (%), 2017 Figure 9.15. Novartis AG: Geographical Presence Share (%), 2017 Figure 9.16. Pfizer Inc., Historical Revenue, ($m), 2013-2017 Figure 9.17. Pfizer Inc.: Product Segments Share (%), 2017 Figure 9.18. Pfizer Inc.: Geographical Presence Share (%), 2017 Figure 9.19. Bayer AG: Historical Revenue, ($m), 2013-2017 Figure 9.20. Bayer AG: Product Segments Share (%), 2017 Figure 9.21. Bayer AG: Geography Presence Share (%), 2018 Figure 9.22. AstraZeneca Plc.: Historical Revenue, ($m), 2013-2017 Figure 9.23. AstraZeneca Plc.: Product Segments Share (%), 2017 Figure 9.24. AstraZeneca Plc.: Geographical Presence Share (%), 2017 Figure 9.25. Eli Lilly and Company: Historical Revenue ($m), 2013-2018 Figure 9.26. Eli Lilly and Company: Product Segments Share (%), 2017 Figure 9.27. Eli Lilly and Company: Geographical Presence Share (%), 2017 Figure 9.28. Advaxis, Inc.: Historical Revenue ($m), 2014-2017 Figure 9.29. Advaxis, Inc.: Product Segments Share (%), 2017 Figure 10.1 World Cancer Immunotherapy by Technology: ($m), 2018-2029 Figure 10.2 World Cancer Immunotherapy by Application: ($m), 2018-2029 Figure 10.3 World Cancer Immunotherapy by End-User: ($m), 2018-2029 Figure 10.4 World Cancer Immunotherapy by Geography: ($m), 2018-2029
Abbott Laboratories Adaptimmune Therapeutics plc Admune Therapeutics Aduro Biotech Advaxis Inc. Alcon Amgen Astrazeneca UK Bayer AG Baylis Medical BioInvent International BioNTech AG. Biothera Bristol-Mayers Squibb cCAM Biotherapeutics Ltd. Celgene Dendreon Dragonfly Eli Lilly Endocyte, Inc F. Hoffmann-La Roche Ltd Flexus Biosciences, Inc. Genentech (Roche) Genomic Health, Inc. GlaxoSmithKline Incyte IOmet Pharma Ltd Janssen Biotech, Inc. Medtronic Merck & Co., Inc. Merck Sharp & Dohme Limited Moderna Therapeutics NextCure Novartis AG Novartis Pharms Corp Palobiofarma Pfizer, Inc. Qiagen N.V. Regeneron Pharmaceuticals Inc Sandoz Sellas Teva Pharmaceuticals Limited Valeant Pharmaceuticals international
List of Organizations Mentioned in the Report American Association of Cancer Research American Cancer Society American Institute for Cancer Research Association of American Cancer Institutes Canadian Cancer society Cancer Research Institute CDC China Center for Food and Drug International Exchange (CCFDIE) Chinese American Hematologist and Oncologist Network (CAHON) European Commission FDA Fred Hutchinson Cancer Research Center National Cancer Institute Parker Institute for Cancer Immunotherapy Seattle Cancer Care Alliance Seattle Children’s Hospital The German Cancer Research Center University of Chicago University of Washington Medical Center WHO
Download sample pages
Complete the form below to download your free sample pages for Global Cancer Immunotherapy Market Forecast 2019-2029
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
